If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan and Russ Mould discusses one of the hardest hit sectors in this sell off
Cathal Friel, Executive Chairman of Open Orphan (ORPH) discusses the new contract they've signed which has the potential to deliver a minimum of £7m.
Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.
Russ Mould, Investment Director at stockbroker AJ Bell talks about one of the hardest hit sectors in this sell off, travel and in particular airlines.
(Interview starts at 11 minutes 41 seconds)